Table 7 Assay results for the estimation of CFZ and PYD in their pharmaceutical formulation by the suggested methods

Kefadim 500 mg IV/IM

102.19

0.19

99.86

0.26

100.26

0.22

90–110% for CFZ

NMT 0.4% for PYD

102.07

0.20

102.09

0.25

100.39

0.21

103.44

0.20

101.42

0.25

100.64

0.22

103.44

0.19

101.61

0.24

100.51

0.22

100.91

0.20

103.08

0.26

100.76

0.22

100.02

0.19

99.82

0.25

101.01

0.22

Mean ± RSD

102.01 ± 1.34

0.20 ± 2.80

101.31 ± 1.26

0.25 ± 2.99

100.59 ± 0.27

0.22 ± 1.86

Kefadim 1.0 g IV/IM

104.85

0.18

99.28

0.27

100.14

0.18

102.79

0.18

100.26

0.26

100.51

0.18

101.67

0.17

101.58

0.27

100.76

0.18

101.85

0.18

103.20

0.26

100.39

0.18

103.58

0.17

101.47

0.26

100.89

0.17

103.26

0.18

102.15

0.27

99.38

0.18

Mean ± RSD

103.00 ± 1.15

0.18 ± 2.92

101.32 ± 1.37

0.27 ± 2.06

100.34 ± 0.54

0.18 ± 2.29